Myeloproliferative neoplasms (MPN), which overproduce blood cells in the bone marrow, have recently been linked with a genetically determined decrease in expression of the MYB transcription factor. Here, we use a mouse MYB knockdown model with an MPN-like phenotype to show how lower levels of MYB lead to stem cell characteristics in myeloid progenitors. The altered progenitor properties feature elevated cytokine responsiveness, especially to interleukin-3, which results from increased receptor expression and increased MAPK activity leading to enhanced phosphorylation of a key regulator of protein synthesis, ribosomal protein S6. MYB acts on MAPK signaling by directly regulating transcription of the gene encoding the negative modulator SPRY2. This mechanistic insight points to pathways that might be targeted therapeutically in MPN.
INTRODUCTION
Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematological disorders characterized by over production of one or more myeloid lineages that can lead to the evolution of myeloid leukemia. Several genetic lesions have been described that lead to the evolution of MPN, exemplified by JAK2 V617F and mutations in calreticulin and the thrombopoietin receptor, MPL. [1] [2] [3] Although the JAK2 V617F mutation is associated with 495% of polycythemia vera and 50-60% of essential thrombocythemia and primary myelofibrosis there are increasing reports of JAK2 V617Fnegative MPN and indeed cases of MPN that are negative for mutations in JAK, MPL and calreticulin. Recently, a study on MPN patients identified potential mutations that predispose to and drive the development of MPN. 4 One of the polymorphisms identified was rs9376092, which is found 75 kb telomeric of the gene encoding the oncogenic transcription factor MYB. Interestingly, this risk allele is associated with reduced MYB RNA expression in both normal myeloid cells and JAK2 V617F mutant BFU-E from essential thrombocythemia patients compared with the equivalent wild-type cells.
Studies on mouse models have suggested that decreased activity of MYB can lead to phenotypes that reflect at least some aspects of MPN. 5, 6 We showed that reduced levels of MYB in mice homozygous for a knockdown allele (MYB KD/KD ) result in a MPNlike disorder resembling human essential thrombocythemia, which is underpinned by a KIT + CD11b + Lin low (K11bL) cell that is stem cell-like. 5 In this study we have sought to understand how a lower level of MYB in myeloid progenitors leads to a gain of stem cell characteristics and the MPN-like phenotype, and thereby shed light on the observed effect of lower MYB levels on the development of human MPN. We further characterize MYB KD/KD K11bL cells and show that enhanced interleukin (IL)-3 signaling is a key consequence of lower MYB activity. The enhanced response to IL-3 is primarily the result of an increase in MAPK signaling. We demonstrate that these changes arise at least in part from reduced activity of the signaling modulator SPROUTY2, the gene expression of which is directly regulated by MYB.
MATERIALS AND METHODS

Sources of hematological tissues
Animal experiments were carried out in accordance with UK legislation. Human umbilical cord blood samples were collected with informed written consent and was approved by the NRES Committee North West-Haydock.
Flow cytometry and cell sorting
This was performed as previously described. 7 All mouse antibodies are listed in Supplementary Table 1 . For human CD34+ cell sorting, we used anti-CD34 PE (BD Biosciences, Oxford, UK).
Phospho-flow analysis
K11bL cells were cultured in serum-free medium for 90 min, and then stimulated with 20 ng/ml IL-3 for 15 min at 37 ºC. Phospho-flow was performed as previously described. 8 Antibodies were PE-conjugated (Cell Signalling Technology, Leiden, The Netherlands). For inhibition experiments, cells were pre-treated with either 1 μM Rapamycin or 10 μM U0126 (Sigma, Poole, UK) in serum-free media at 37°C for 1 h.
Homing assays
Sorted K11bL cells were labeled with 0.3 mg/ml Xenolight DiR (PerkinElmer, Seer Green, UK) for 30 min at 37°C. Cells were washed and resuspended in 150 μl of PBS, and injected via the tail vein into lethally irradiate hosts (B6:SJL). Details of in vivo imaging system conditions can be found in Supplementary Information.
Transfection and cell culture
Human CD34 + were sorted and transfected using the 4D-Nucleofector system (Lonza, Slough, UK) with fFluorescein amidite-labeled small interfering RNAs (Supplementary Table 2 ). Following transfection, CD34 + cells were cultured for 24 h in RPMI supplemented with 10% FBS, 50 ng/ml SCF, 10 ng/ml IL-3 and 20 ng/ml IL6. After 24 h cells were plated in complete methylcellulose (Methocult GF H84435). Colony morphology and number were assessed between 7 and 14 days.
Transduction of bone marrow cells
Lentiviruses (Origene, Rockville, MD, USA) expressing shRNA SPRY2 (TG515588) or Il3ra (TG516353) or SPRY2 ORF together with GFP (green fluorescent protein), were generated as described. 9 Bone marrow or K11bL cells were cultured in the presence of 3 μg/ml Polybrene (Sigma) with lentivirus at an multiplicity of infection of 10. Cells were cultured for 4 h, washed and either injected into lethally irradiated mice or further cultured for 20 h. Infection efficiency was assessed based on GFP expression.
Gene expression analysis
Affymetrix Mouse Gene 1.0 ST array analysis was performed on K11bL cells. The GEO accession number for the data deposited is GSE74140. Further detail can be found in Supplementary Information. Quantitative PCR was performed as previously described. 5 TaqMan PCR primers (Applied Biosystems, Carlsbad, CA, USA) and primer sequences are listed in Supplementary Table 3 .
Cross-linking chromatin immunoprecipitation analysis
Cross-linking chromatin immunoprecipitation assays were performed as previously described 10 using antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-MYB antibody from Merck Millipore (Watford, UK). Primers for detection of MYB binding to the SPRY2 and DUSP6 genes are listed in Supplementary Table 4 .
Statistical analysis
Significance of data sets was assessed using two-tailed unpaired Student's t-test with significance set at Po 0.05.
RESULTS
MYB KD/KD K11bL cells exhibit myeloid bias and have stem cell characteristics
When K11bL cells, which are more abundant in MYB KD/KD mice compared with MYB WT/WT controls (Figure 1a ), were transplanted into lethally irradiated mice they engrafted significantly, irrespective of whether they were MYB WT/WT or MYB KD/KD (Supplementary Figure 1a ). However, engrafted MYB KD/KD K11bL cells gave rise predominantly in the peripheral blood to CD11b + myelomonocytic cells whereas MYB WT/WT K11bL cells largely differentiated into B220 + B-lymphoid cells ( Figure 1b ( Supplementary Figure 1b) . Importantly, when bone marrow isolated from the primary recipients was transplanted into secondary hosts, MYB WT/WT K11bL cells failed to support serial engraftment, whereas MYB KD/KD cells were able to perpetuate the myeloproliferative phenotype ( Supplementary Figure 1c ). We confirmed the MYB KD/KD lineage bias of K11bL cells by in vitro colony assay. MYB KD/KD cells predominantly formed colonies containing macrophage (CFU-M) and CFU-M/Mk colonies, failing to produce colonies of granulocytic or erythroid morphology, whereas MYB WT/WT K11bL cells were able to undergo a full program of myeloid differentiation ( Supplementary Figure 1d ). Microarray analysis of K11bL cells confirmed the shift from a lymphoid to a myeloid bias, Gene Ontogeny (GO) analysis showing that compared with MYB WT/WT K11bL cells, MYB KD/KD cells exhibit higher expression of genes associated with myeloid differentiation, and reduced levels of lymphoid-associated genes (Supplementary Table 5 ).
We sought to identify the differences in surface marker and gene expression that might explain the stem cell-like transplantation behavior of MYB KD/KD K11bL cells (Figure 1ci and Supplementary Figure 1e ). MYB KD/KD K11bL cells have higher levels of expression of the integrins CD51 (α V ), CD41 (αIIb) and CD61 (β3) and the adhesion molecule CD62 (P-selectin). As MYB KD/KD K11bL cells have gained stem cell properties, we analyzed the microarray for expression of homing and bone marrow retention molecules together with flow cytometric analysis of some of the key proteins. Analysis of RNA expression data for the GO group 'cell chemotaxis' (GO:0060326) revealed an increase in expression of genes associated with homing and invasion of extramedullary sites of hematopoiesis (for example, Ccr1) and lower levels of genes regulating bone marrow retention (for example, Vcam1) (Supplementary Table 6 ). Flow cytometric analysis confirmed the reduction of VCAM1 on the surface of MYB KD/KD K11bL cells (Figure 1cii and Supplementary Figure 1e ). Consistent with their stem cell characteristics, MYB KD/KD K11bL cells have higher levels of SCA1 and CD34, and exhibit a small but significantly higher level of the SLAM marker CD150 (P ⩽ 0.01) ( Figure 1ciii and Supplementary Figure 1e ).
MYB KD/KD K11bL cells have an enhanced response to IL-3
Interestingly, analysis of genes in the GO group 'cytokinemediated signaling pathway' (GO:0019221) revealed that a number of cytokine receptor genes are more highly expressed in MYB KD/KD K11bL cells compared with the MYB WT/WT equivalent. Among these genes we identified CSF2RB (IL3RBC) as being more highly expressed in MYB KD/KD K11bL cells (2.25-fold P = 7 × 10 − 5 Supplementary Table 7 ). This difference, together with that of the other IL-3 receptor component IL3RA, was confirmed by quantitative PCR (Figure 2a ). Correspondingly, immunofluorescence analysis showed that the expression of IL3RA (CD123) and CSF2RB (CD131) are greater on MYB KD/KD K11bL cells than the MYB WT/WT equivalents ( Supplementary Figure 2a ).
It is well documented that malignant cells can exhibit a heightened response to growth factors, augmenting their proliferation and survival. Our observations on altered IL-3 receptor expression on MYB KD/KD K11bL cells combined with the fate of the cells following transplantation led us to ask if altered responses to IL-3 could be dictating stem cell characteristics. When we plated cells in semi-solid media containing a range of concentrations of IL-3, this revealed that MYB KD/KD K11bL cells have a heightened response to the cytokine as manifested by higher colony numbers. This enhancement was significant at all concentrations tested down to 0.02 ng/ml (P ⩽ 0.05) ( Figure 2b ). Analysis of colony morphology showed that MYB WT/WT K11bL cells yielded colonies containing granulocytes (CFU-G), macrophage (CFU-M), and a mix of both of these cell types (CFU-GM). In contrast, MYB KD/KD cells formed mainly CFU-M, which were highly proliferative and gave rise to disperse colonies as well as a few colonies containing both macrophages and megakaryocytes ( Figure 2c ).
IL-3 signaling is critical for MYB KD/KD K11bL cell function
To determine how dependent MYB WT/WT and MYB KD/KD K11bL cells are on signaling through the IL-3 receptor, even in the presence of other growth factors, we used a neutralizing antibody against the IL-3 receptor subunit IL3RB to inhibit the response to IL-3. We observed a marked reduction in colony number from 19 ± 1 to 8 ± 0 (P = 0.004) for MYB KD/KD K11bL cells, but saw no effect on MYB WT/WT cells (Figure 3a ), suggesting that MYB KD/KD K11bL cells are critically dependent on signaling through the IL-3 receptor.
As IL3RB is common to signaling through both the IL-3 and GM-CSF receptors, we wanted directly to assess the effect of knocking down the other IL-3-specific subunit, IL3RA. MYB KD/KD K11bL cells were transduced with lentivirus expressing IL3RA shRNA and were then transplanted into lethally irradiated mice. Co-expression of GFP from the shRNA vector indicated that we achieved a transduction rate of~70% (Figure 3bi ). Engraftment was apparent after 1 month, however the proportion of donor cells in the peripheral blood was markedly reduced when IL3RA was knocked down. By 3 months this difference was more evident (Figure 3bii ). Interestingly, MYB KD/KD donor cells expressing shRNA IL3RA had a significantly reduced differentiation toward monocytes (Gr1 − CD11b + ) compared with control cells (69 ± 3% compared with 57 ± 2%, P ⩽ 0.01) and a corresponding increase in differentiation toward granulocytes (Gr1 + CD11b + ) ( Supplementary  Figure 2b ). Similar to previous observations, the ratio of shRNA control transduced donor MYB KD/KD cells rapidly increased between 1 and 7 months following transplantation, whereas the cells expressing shRNA IL3RA were maintained at their low engraftment ratio, indicating a necessity for the expression of IL3RA for engraftment of MYB KD/KD K11bL cells ( Supplementary Figure 2c) .
The influence of enhanced IL-3 signaling on engraftment was further examined with respect to short-term migration and homing following transplantation. Following injection of fluorescently labeled K11bL cells it was evident after one hour that the MYB KD/KD cells have distinct homing behavior compared with MYB WT/WT K11bL cells, with the predominant signal emanating from the spleen. Using the IL3RB blocking antibody we then showed that active signaling through IL3RB is required for the ability of MYB KD/KD K11bL cells to home toward the spleen as evidenced by a loss of fluorescence signal (9 ± 1 to 0.44 ± 0.2 photon/s P = 0.007) when IL3RB was blocked (Figure 3c and Supplementary Figure 2d ).
Signaling downstream of the IL-3 receptor is enhanced in MYB KD/KD K11bL cells We used phospho-flow cytometry to determine whether the enhanced response of MYB KD/KD K11bL cells is reflected in the phosphorylation status of molecules that could influence the interpretation of IL-3-mediated signaling. The only significant difference in steady-state phosphorylation was observed in rpS6 Ser235/236 and STAT5 Tyr694 , the former exhibiting a median fluorescence intensity (MFI) of 18.9 ± 1.1 in MYB WT/WT K11bL cells versus 52.5 ± 2.4 (P = 0.003) in MYB KD/KD cells and the latter being 26.4 ± 1.5 in MYB WT/WT compared with 47.9 ± 0.3 (P = 0.0026) in MYB KD/KD cells ( Supplementary Figure 3a) .
In order to assess the effect of IL-3 stimulation on the dynamics of phosphorylation, K11bL cells were starved of serum prior to stimulation with IL-3 and subsequent analysis 15 min later. We observed differences in both the extent of the response and the relative degree of phosphorylation of rpS6 Ser235/236 and rpS6 Ser240/244 . Hence, stimulation of K11bL cells with IL-3 led to an increase in rpS6 Ser235/236 phosphorylation, reflected in a MFI shift of 105 ± 36 to 232 ± 32 (P = 0.009) for MYB WT/WT and 91 ± 29 to 480 ± 82 (P = 0.0002) for MYB KD/KD (Figure 4ai and Supplementary  Figure 3b ). This also revealed that MYB KD/KD K11bL cells showed a significantly greater increase in the proportion of cells phosphorylated at this site and reached an overall higher level of phosphorylation, the MFI being twice as great as that seen in MYB WT/WT K11bL cells (P = 0.0063; Supplementary Figure 3b ). We therefore also checked for changes in phosphorylation at the rpS6 Ser240/244 site. Following IL-3 stimulation, no significant increase in phosphorylation was seen in MYB WT/WT K11bL cells, whereas MYB KD/KD K11bL cells demonstrated a small increase, seen as a shift in MFI of 13.3 ± 3 to 22.9 ± 4 (P = 0.02) (Figure 4ai and Supplementary Figure 3c ).
Phosphorylation of rpS6 Ser235/236 can occur through activation of the PI3k/AKT/mTOR or RAS/MAPK pathways, whereas only the former leads to the modification of rpS6 Ser240/244 . 11 We examined the phosphorylation status of AKT (Thr308 and Ser473) and p44/42 MAPK (ERK1/2) to investigate the relative use of the two pathways. At 15 min post IL-3 stimulation we failed to detect any phosphorylation of AKT or p44/42 MAPK (data not shown). However, reasoning that the response to IL-3 might be very rapid, we also looked at phosphorylation at 5 min following IL-3 addition. A significant increase in phosphorylation of AKT Thr308 was seen as a shift in MFI from 6.7 ± 1.5 to 13.8 ± 4.5 (P = 0.047) (Figure 4aii and Supplementary Figure 3d ). We also observed an increase in the percentage of cells positive for p44/42 MAPK phosphorylation from 4 ± 3 to 23 ± 5% (P = 0.04) in MYB KD/KD K11bL cells but not in the MYB WT/WT equivalent (Figure 4aii and Supplementary Figure 3e) .
To confirm the dependence of rpS6 phosphorylation on the PI3k/AKT/mTOR and RAS/MAPK pathways and better to define how the specificity and balance of activity differs in MYB KD/KD K11bL cells compared with MYB WT/WT cells, we performed IL-3 stimulations following pre-treatment of the K11bL cells with inhibitors of mTOR (Rapamycin) or MEK (U0126). Treatment of MYB WT/WT cells with Rapamycin but not U0126 resulted in a loss of phosphorylation of rpS6 Ser235/236 from 21.8 ± 3.2 to 12.5 ± 2.7% (P = 0.02, Supplementary Figure 3f ). Similar analysis of rpS6 in MYB KD/KD K11bL cells showed that phosphorylation at Ser235/236 was inhibited by U0126 (45.5 ± 7.1 to 13.7 ± 3.5%; P = 9.5 × 10 À 05 ) but not by rapamycin, whereas the Ser240/244 site modification was susceptible to inhibition of mTOR but not MEK (Figure 4b and Supplementary Figure 3f ). This implies that one aspect of the distinctive cytokine responsiveness seen in MYB KD/KD K11bL cells relates to a shift in the relative usage of the signaling pathways downstream of the IL-3 receptor. The baseline phosphorylation of STAT5 Tyr694 was lower in MYB KD/KD K11bL cells but upon stimulation with IL-3 increased to a level similar to that seen in MYB WT/WT cells following their treatment with cytokine ( Figure 4ci ). Consistent with the phosphorylation of STAT5 being elicited through a JAK protein, we observed no effect on the level of phosphorylation in the presence of the mTOR or MEK inhibitors (Figure 4cii ).
The expression of signaling-associated genes defines the MYB KD/KD K11bL phenotype Based on the phosphorylation results, we further analyzed the array data to look at GO groups associated with signaling. Analysis of deregulated genes involved in intracellular signal transduction (GO:1902532) ( Supplementary Table 8 ) and in particular proteins involved in the ERK signaling cascade (GO:0070372) ( Supplementary Table 9 ) highlighted the altered expression of several genes. In particular, we noted that MYB KD/KD K11bL cells exhibit lower expression of the genes encoding the inhibitor SPROUTY2 (SPRY2), the dual specificity phosphatase 6 (DUSP6), and the RAS protein activator (RASA2), and higher expression of dual specificity phosphatase 3 (DUSP3), and suppressor of cytokine signaling 3 (SOCS3).
In order to confirm which of these differences might reflect direct regulation by MYB we used our conditional MYB knockout. 12 K11bL cells were isolated from control mice (MYB +/+ :Cre) and MYB knockout (MYB F/F :Cre) mice 24 h after induction of deletion, and the levels of RNA for MYB and the selected genes were measured by quantitative RT-PCR. This confirmed that SPRY2 and DUSP6 RNA levels were depleted, whereas the levels of IL3RA, CSF2RB, CSFR2RB2, CSFR1, SOCS3, DUSP3, MECOM and CCND1 were higher, suggesting that the expression of these genes could be directly inhibited by MYB (Figure 5a ).
MYB directly regulates expression of the SPRY2 and DUSP6 genes We next used cross-linking chromatin immunoprecipitation to determine whether positive regulation of the SPRY2 and DUSP6 genes by MYB correlates with binding of the protein to gene regulatory regions. We prepared chromatin from the murine HSC line HPC-7, 13 and used an antibody against MYB for immunoprecipitation of SPRY2 and DUSP6 gene fragments corresponding to in vivo binding sites for the factor. Primers for quantitative PCR were designed around highly conserved regions that contained potential MYB-binding sequences. In this way, we demonstrated MYB binding to the SPRY2 promoter (−0.55 kb from ATG, Figure 5b ) and the DUSP6 promoter (−2.7 kb from ATG, Figure 5c ), whereas there was no significant enrichment of either the SPRY2 enhancer (−26 kb from ATG) or the DUSP6 distal promoter (−2.7 kb from ATG) ( Supplementary Figure 4) .
Reduced MYB expression in human progenitors mirrors the changes seen in MYB KD/KD K11bL cells
To examine if our observations in the mouse system are paralleled in human cells we transfected CD34+ cord blood cells with MYB small interfering RNA. This achieved a 50% reduction in MYB gene expression at 24 h, and upon plating cells in methylcellulosecontaining myeloid growth factors we observed that knockdown of MYB leads to an increase in CFU-M and CFU-Mk and a reduction in CFU-G, CFU-GEMM and BFU-E, in line with the broad phenotypic changes seen in MYB KD/KD K11bL cells (Figure 6a ). We also showed that the knockdown of MYB in the human cells led to a significant decrease in the expression of SPRY2 and increased expression of IL3RA and CSF1R, exactly as we saw in murine MYB KD/KD K11bL cells, however, unlike in mouse K11bL cells, the expression of DUSP6 was significantly increased (Figure 6b ).
Manipulation of SPRY2 expression in MYB WT/WT cells partially recapitulates the MYB KD/KD stem cell phenotype Based on the apparent importance of enhanced IL-3-dependent RAS/MAPK signaling in MYB KD/KD K11bL cells and the conserved MYB-dependent expression of SPRY2 in both mouse and human progenitor cells, we reasoned that SPRY2 is pivotal to the way in which IL-3 can influence stem cell characteristics of myeloid progenitors. In order to assess the degree to which SPRY2 is responsible for the gain of stem cell function, we transduced MYB WT/WT K11bL cells with a lentiviral vector expressing shRNA directed against SPRY2 and assayed their ability to form hematopoietic colonies in vitro. MYB WT/WT K11bL cells transduced with control virus demonstrated normal colony formation in complete methylcellulose. In contrast, MYB WT/WT cells transduced with lentivirus expressing SPRY2 shRNA (which exhibited 495% knockdown- Supplementary Figure 5a ) demonstrated reduced CFU-G colonies and increased CFU-M colonies, similar to the situation seen for MYB KD/KD K11bL cells (Figure 7a ). Secondary plating of MYB WT/WT K11bL cells experiencing SPRY2 knockdown resulted in colonies that covered the plate, whereas control cells formed very small, sparsely distributed colonies ( Supplementary  Figure 5b) . These SPRY2 knockdown MYB WT/WT K11bL secondary colonies showed increased levels of KIT and CD34 compared with the control cells ( Supplementary Figure 5c ). Transplantation assays of MYB WT/WT K11bL cells transduced with control or SPRY2 shRNA revealed a higher donor to reference ratio when levels of SPRY2 were reduced (Figure 7b ). This enhanced engraftment was further amplified by 3 months but the contribution to peripheral myeloid cells (CD11b+) was not altered (Supplementary Figure 5d ). Secondary transplantation revealed the acquisition of long-term repopulating ability by the SPRY2 knockdown K11bL cells ( Supplementary Figure 5e ). We then asked if overexpression of SPRY2 in MYB KD/KD K11bL cells could reverse their proliferation and differentiation characteristics. Colony forming assays of MYB KD/KD K11bL cells transduced with a lentivirus expressing SPRY2 resulted in a significant reduction in colony number in complete methylcellulose (Figure 7c ). In addition, the SPRY2-overexpressing MYB KD/KD K11bL cells gave rise to a lower proportion of megakaryocyte colonies and increased granulocytic colonies compared with K11bL cells infected with control virus (Figure 7c ).
DISCUSSION
MYB was originally shown to be a critical regulator of hematopoiesis, as complete ablation abolished definitive hematopoiesis. 14 The role that MYB has in adult hematopoiesis has been studied using mouse models with reduced activity of the protein, 5, 6, 12, 15 revealing a role for MYB in immature proliferating hematopoietic cells. Here we have sought to link recent observations on the genetic predisposition to MPN caused by lower levels of expression of MYB 4 with the phenotype seen in our mouse model for decreased MYB activity. We show that lower MYB levels in myeloid progenitors results in; (i) altered short-term homing toward the spleen, (ii) differentiation toward myelomonocytic cells and (iii) a stem cell phenotype, including selfrenewal potential that is not seen in the normal equivalents and giving a phenotype more similar to those described in some chronic myeloid leukemia and acute promyelocytic leukemia stem cells. 16, 17 Key to the MYB KD/KD phenotype is altered IL-3 signaling, particularly along the RAS/MAPK pathway. Our results suggest that enhanced IL-3 signaling is responsible for aspects of the aberrant stem cell phenotype, including homing to the spleen, engraftment potential and lineage bias. Such acquired properties likely have relevance to the leukemia stem cell-specific role of IL-3 receptor in acute myeloid leukemia, which has been shown to be an effective target for an anti-IL3RA (CD123) antibody. 18 We are presently investigating the mechanisms by which increased IL-3-dependent signaling leads to the MYB KD/KD phenotype. The RAS/MAPK pathway appears to be central and, although the nature of the critical targets remains unclear, we found evidence for the activation of ribosomal protein S6, which itself has an essential role in protein translation of several prosurvival protein genes such as MYC, BCL-XL and SURVIVIN, and might therefore contribute to the gain of stem cell properties. Interestingly, there are descriptions of the importance of ERK/ MAPK in self-renewal of both embryonic and adult stem cells. 19, 20 Reference:Donor Ratio Figure 6 . (a) Human CD34+ cells were isolated from human umbilical cord blood by FACS and transfected with either siRNA control or siRNA MYB and after 24 h FAM+ cells were plated in complete methylcellulose and assayed for their ability to undergo full myeloid differentiation after 10 days in culture. (b) Cells were also collected at 24 h for the preparation and analysis of RNA expression. The histograms illustrate quantitative RT-PCR measurements of RNA expression for the MYB, SPRY2, DUSP3, DUSP6, IL3RA and CSF1R genes **P ⩽ 0.001, **** P ⩽ 0.0001.
Relative RNA expression
The RAS/MAPK pathway is frequently activated in hematological malignancy and has been implicated in the sensitivity and resistance of cells to therapy, 21 including in other MPN models such as the KRAS mutant mouse. 22 We explored the mechanisms by which reduced MYB activity leads to enhanced IL-3 signaling, and found that these involved multiple direct and indirect targets, and including both positively and negatively regulated genes. Aside from what appears to be coordinated positive regulation of several cytokine receptor genes, MYB also normally seems to provide a coordinated controlling influence on RAS/MAPK signaling by promoting the expression of negative pathway regulators, including SPRY2 and DUSP6. SPRY2, which prevents the interaction between RAS and GRB2-SOS 23 following their recruitment by SHC when it associates with the IL-3 receptor, seems to be relevant in both the mouse and human systems we examined. The lower expression of SPRY2 would be expected to release the inhibition of RAS, leading to an increased sensitivity to IL-3. Interestingly, knockdown of SPRY2 in wild-type progenitor cells both shifted their phenotype and enhanced engraftment potential, partially reflecting the overall phenotype of the MYB KD/KD cells.
We postulate a working model for the signaling pathways utilized in K11bL cells in both MYB WT/WT and MYB KD/KD mice (Figure 8 ), and clearly our study has opened up a whole new chapter in the understanding of the pivotal role of MYB in both normal and malignant hematopoiesis. Although numerous additional mechanisms undoubtedly combine to give rise to the complete MYB KD/KD MPN-like phenotype, our findings suggest that IL-3-dependent signaling has a major role, affecting the regulation of genes responsible for migration, proliferation and differentiation. For those hematological disorders where MYB activity is affected, including MPN, the knowledge that signaling downstream of IL-3 receptor is affected as a direct result of altered MYB levels could open up the possibility for a more direct approach to treatment. 
